Pekin Hardy Strauss Inc. trimmed its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 53.5% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 10,179 shares of the biopharmaceutical company's stock after selling 11,716 shares during the period. Pekin Hardy Strauss Inc.'s holdings in Pfizer were worth $258,000 at the end of the most recent quarter.
Several other institutional investors have also bought and sold shares of PFE. Clarity Asset Management Inc. purchased a new stake in Pfizer in the 4th quarter worth $27,000. Gould Capital LLC boosted its position in Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 493 shares during the period. North Capital Inc. acquired a new stake in Pfizer during the 1st quarter worth $28,000. Bernard Wealth Management Corp. purchased a new position in Pfizer during the 4th quarter worth $30,000. Finally, Curio Wealth LLC purchased a new stake in Pfizer during the fourth quarter worth about $32,000. Institutional investors own 68.36% of the company's stock.
Wall Street Analyst Weigh In
A number of equities research analysts recently weighed in on the stock. Leerink Partners lowered their price target on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a report on Wednesday, April 30th. Citigroup raised their target price on shares of Pfizer from $23.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. The Goldman Sachs Group lifted their target price on shares of Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Jefferies Financial Group upped their target price on shares of Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a report on Wednesday, May 21st. Finally, Morgan Stanley upped their target price on shares of Pfizer from $31.00 to $32.00 and gave the company an "equal weight" rating in a research report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Pfizer currently has a consensus rating of "Hold" and a consensus price target of $28.55.
Check Out Our Latest Stock Report on Pfizer
Pfizer Stock Performance
Shares of PFE stock opened at $25.61 on Wednesday. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The company's fifty day moving average price is $23.80 and its two-hundred day moving average price is $24.81. The firm has a market capitalization of $145.60 billion, a P/E ratio of 18.56, a P/E/G ratio of 0.92 and a beta of 0.58.
Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The firm had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same quarter in the prior year, the business earned $0.82 EPS. The company's revenue for the quarter was down 7.8% compared to the same quarter last year. On average, research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.
Pfizer Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.72%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's payout ratio is currently 124.64%.
About Pfizer
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Further Reading
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
